Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role

Endocrine therapy (ET) is a pivotal strategy to manage early- and advanced-stage estrogen receptor-positive (ER+) breast cancer. In patients with metastatic breast cancer (MBC), progression of disease inevitably occurs due to the presence of acquired or intrinsic resistance mechanisms. ET resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Lloyd, Maxwell R., Wander, Seth A., Hamilton, Erika, Razavi, Pedram, Bardia, Aditya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340905/
https://www.ncbi.nlm.nih.gov/pubmed/35923930
http://dx.doi.org/10.1177/17588359221113694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340905/
https://www.ncbi.nlm.nih.gov/pubmed/35923930
http://dx.doi.org/10.1177/17588359221113694

Ejemplares similares